TAK EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
TAK's ev/ebitda is higher than 65% of the last 10 years.
EV/EBITDA History
TAK EV/EBITDA by year
Yearly range of TAK’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 7.2 to 26.8, averaging 11.9.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 8.6 | 9.6 | 10.9 | 10.8 |
| 2025 | 8.6 | 9.4 | 10.4 | 8.6 |
| 2024 | 8.4 | 9.9 | 11.2 | 9.0 |
| 2023 | 8.7 | 9.3 | 10.2 | 9.4 |
| 2022 | 7.5 | 9.0 | 10.2 | 9.8 |
| 2021 | 7.2 | 9.4 | 13.0 | 7.5 |
| 2020 | 11.9 | 15.1 | 17.5 | 11.9 |
| 2019 | 14.6 | 20.2 | 26.8 | 17.1 |
| 2018 | 9.7 | 12.5 | 15.0 | 14.8 |
| 2017 | 10.4 | 13.0 | 15.0 | 13.5 |
| 2016 | 9.8 | 12.5 | 21.0 | 10.1 |
Get notified when TAK EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is TAK EV/EBITDA High or Low Right Now?
Takeda Pharmaceutical Company Limited's EV/EBITDA is currently 10.8, which is above average relative to its 10-year historical range. The 10-year median EV/EBITDA for TAK is approximately 10.3. See all TAK valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.